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This commentary is written to accom-
pany a special research topic, Second Hand
Smoke and COPD: lessons from animal
studies, hosted by Frontiers in Respiratory
Physiology.
Model systems allow researchers to
study disease, to tease out cause and effect
and mechanisms of action, and to con-
duct the preliminary studies of the safety
and efficacy of treatments. The underly-
ing objective of the research is, of course,
to improve healthcare outcomes. Pointing
out the difficulty of studying a disease that
takes decades to develop in humans, this
collection of articles focuses on what has
been learned from studies using models
of COPD. It also presents an opportunity
to circle back to the implications of the
research and to ask a most basic ques-
tion: do healthcare providers recognize the
impact of second hand smoke (SHS) expo-
sure on health and, if they do, are they
asking the right questions?
The 2006 Surgeon General’s Report,
“Health Consequences of Involuntary
Exposure to Tobacco Smoke” (Surgeon
General, 2006) documents the health
implications of exposure to SHS, includ-
ing firm evidence that SHS contributes
to coronary and lung disease, lung can-
cer, premature death in adults, slow lung
development, SIDS, asthma, and ear infec-
tions in children, as well as suggestive
evidence that implicate SHS in COPD,
asthma, breast cancer, and nasal sinus can-
cer in adults, and leukemia, lymphoma,
and brain tumors in children. The report
indicates that there is no risk-free level
of SHS.
Despite evidence that SHS is a risk
factor for disease, most healthcare orga-
nizations and many physicians fail to
ask patients about their history of SHS
exposure. The implications of that fail-
ure are considerable because knowledge
of a patient’s history of SHS exposure
enables providers to make better-informed
decisions about what to include in each
patient’s examination and lab tests, and
how to conduct long-term monitoring, as
well as alerting the patient to the need
for measures to help them avoid further
smoke exposure.
An example of a medical history of
SHS exposure on health status can be
seen in the development of lung disease
in flight attendants, a group who histori-
cally worked in SHS filled aircraft. Recent
research has revealed decreased exercise
tolerance, decreased diffusing capac-
ity with decreased pulmonary capillary
recruitment as well as air trapping and air-
way obstruction in never-smoking flight
attendants who were exposed prior to the
ban on smoking in aircraft (Arjomandi
et al., 2009, 2012). US aircraft became
smoke-free by 1990 for flights less than 6 h,
and by 2000 all US carriers were required
to be smoke-free. These flight attendants,
despite never smoking, have evidence
of lung disease 10–20 years after their
SHS exposure. For patients with a his-
tory of SHS exposure, failure of providers
to include the right questions may leave
risks hidden and opportunities for early
intervention lost.
The American Academy of Pediatrics
(AAP) has pioneered efforts to encour-
age physicians to ask the right questions
regarding the exposure of children to SHS.
Recognizing that SHS is a major contribu-
tor to childhood morbidity and mortality,
the AAP hasmade asking about SHS expo-
sure an essential part of regular pediatric
care. This practice of asking the right ques-
tions could serve as a model for healthcare
providers worldwide.
Prevention of disease progression due
to SHS of course has clear implications for
patients’ suffering and their ability to con-
tinue to function in society. SHS exposure
also has significant financial implications
for healthcare payers. As the health care
system in the US moves from a fee-for-
service to a fee-for-results structure, pre-
vention of disease and promotion of well-
ness become much more important. Early
recognition of the presence of risk factors
for the development of tobacco smoke-
related disease enables intervention before
more severe conditions arise; from the
most pragmatic perspective, advanced dis-
ease is simply more costly to treat.
The importance of asking about SHS
exposure is not limited to clinical care.
Researchers too can improve study design
and outcomes when they recognize the
impact of SHS exposure. In human stud-
ies that look for risk factors for disease, the
failure to ask about an individual’s history
of SHS exposure may lead to confusing or
less significant results. For instance, when
looking for the impact of smoking on can-
cer incidence, osteoporosis, or lung dis-
ease, placing those who have been exposed
to SHS in the category “non-smoker,” as
many studies have done, simply makes no
sense.
Additional reason for asking about a
history of SHS exposure is suggested by
the links between Vitamin D deficiency
and the development of COPD. Our own
laboratory has recently focused on the
impact of Vitamin D deficiency on the
development and progression of SHS-
related emphysema in a mouse model.
Epidemiologic studies by Janssens and
colleagues demonstrated low serum levels
of 25-hydroxyvitamin D in advanced stage
COPD patients, as well as an increased
incidence of COPD in individuals who
carry a mutation in one or more of the
genes involved in vitamin D metabolism
(Janssens et al., 2009a, 2011). Our model
of cigarette smoke exposure with vitamin
D deficiency supports the hypothesis that
low levels of 25-hydroxyvitamin D may
contribute to the severity of SHS-related
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emphysema. Given the multiple roles of
vitamin D in infection, cardiovascular dis-
ease, and osteoporosis (all comorbidities
of COPD), it seems prudent for health
care providers to screen for vitamin D
levels in at-risk patients (Holick, 2004;
Lee et al., 2008; Janssens et al., 2009b).
Without knowing a patient’s history of
SHS exposure, vitamin D screening might
not be considered.
COPD is the third leading cause of
death worldwide. While lung damage from
COPD is irreversible, recognition of the
early stages of the disease allows providers
to intervene so as to slow or arrest dis-
ease progression. While smoking is widely
acknowledged as a risk factor, the danger
of SHS exposure is significantly under-
recognized. Since the initial symptoms of
COPD are hard to detect, increased aware-
ness of SHS exposure as a risk factor
should alert caregivers to screen for early
signs of disease. This would give them
an earlier indicator of increased disease
risk and provide crucial additional time in
which to mitigate the onset and progres-
sion of disease. Counseling to avoid smoke
exposure, monitoring for early evidence of
changes in lung function, vitamin Dmoni-
toring, and early inclusion of interventions
such as exercise, respiratory training, and
mind-body practices such as Qigong or Tai
Chi, can all be part of a strategy to control
the disease process.
There is an ongoing emphasis on
improving outcomes and lowering costs of
health care. The AAP has taken the lead
in encouraging a simple and inexpensive
approach to lowering the impact of SHS
exposure: simply talking to patients about
it and taking it into account when con-
sidering the patient’s overall health. It’s a
winning strategy; asking about the history
of SHS exposure as part of the course of
regular care would give providers greater
opportunities for early intervention and
patients opportunities for improved long-
term health.
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